Academy Capital Management Raised Its National (NOV) Stake by $606,305; Balyasny Asset Management Increased Holding in Nektar Therapeutics (NKTR) by $6.76 Million as Share Value Rose

February 15, 2018 - By David Stenberg

Dmitry Balyasny increased its stake in Nektar Therapeutics (NKTR) by 55.14% based on its latest 2017Q3 regulatory filing with the SEC. Balyasny Asset Management Llc bought 281,769 shares as the company’s stock rose 44.66% with the market. The hedge fund run by Dmitry Balyasny held 792,782 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $19.03 million, up from 511,013 at the end of the previous reported quarter. Balyasny Asset Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be bullish on the $13.16B market cap company. The stock decreased 0.54% or $0.45 during the last trading session, reaching $83.55. About 1.52M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since February 15, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Academy Capital Management Inc increased its stake in National (NOV) by 3.17% based on its latest 2017Q3 regulatory filing with the SEC. Academy Capital Management Inc bought 17,323 shares as the company’s stock declined 11.45% while stock markets rallied. The institutional investor held 563,557 shares of the energy company at the end of 2017Q3, valued at $20.14M, up from 546,234 at the end of the previous reported quarter. Academy Capital Management Inc who had been investing in National for a number of months, seems to be bullish on the $13.18 billion market cap company. The stock decreased 1.28% or $0.45 during the last trading session, reaching $34.69. About 1.73 million shares traded. National Oilwell Varco, Inc. (NYSE:NOV) has risen 11.97% since February 15, 2017 and is uptrending. It has underperformed by 4.73% the S&P500.

Academy Capital Management Inc, which manages about $542.59 million and $355.31 million US Long portfolio, decreased its stake in Zoetis (NYSE:ZTS) by 97,911 shares to 100,192 shares, valued at $6.39M in 2017Q3, according to the filing.

Investors sentiment increased to 0.85 in Q3 2017. Its up 0.18, from 0.67 in 2017Q2. It improved, as 53 investors sold NOV shares while 189 reduced holdings. 49 funds opened positions while 157 raised stakes. 348.73 million shares or 2.54% more from 340.10 million shares in 2017Q2 were reported. Buckhead Cap Management Ltd Liability Corporation, a Georgia-based fund reported 34,297 shares. Hudock Ltd Liability Corp has 0% invested in National Oilwell Varco, Inc. (NYSE:NOV) for 33 shares. Bluestein R H & Company holds 0.07% in National Oilwell Varco, Inc. (NYSE:NOV) or 34,100 shares. Tci Wealth Advsr Inc reported 178 shares. Cambridge Invest Research Advisors holds 0% or 9,625 shares. Dubuque Comml Bank And Trust holds 0.72% or 122,538 shares. Bnp Paribas Asset Sa holds 17,181 shares or 0.01% of its portfolio. Moreover, Hall Laurie J Trustee has 0.01% invested in National Oilwell Varco, Inc. (NYSE:NOV) for 340 shares. The Connecticut-based Hartford Fincl has invested 0% in National Oilwell Varco, Inc. (NYSE:NOV). Korea reported 13,105 shares stake. Overbrook Mgmt has invested 0.1% in National Oilwell Varco, Inc. (NYSE:NOV). Qs Invsts Ltd Co owns 117,192 shares for 0.03% of their portfolio. Blackrock holds 25.18M shares. Northwestern Mutual Wealth Mgmt accumulated 0% or 1,796 shares. Forte Capital Limited Liability Adv reported 0.1% of its portfolio in National Oilwell Varco, Inc. (NYSE:NOV).

Among 34 analysts covering National Oilwell Varco (NYSE:NOV), 10 have Buy rating, 5 Sell and 19 Hold. Therefore 29% are positive. National Oilwell Varco had 119 analyst reports since July 31, 2015 according to SRatingsIntel. On Wednesday, May 31 the stock rating was maintained by Jefferies with “Hold”. The firm has “Hold” rating by Tudor Pickering given on Friday, March 24. Loop Capital upgraded National Oilwell Varco, Inc. (NYSE:NOV) on Thursday, August 17 to “Buy” rating. The rating was upgraded by Guggenheim on Monday, November 30 to “Buy”. The stock has “Sell” rating by BMO Capital Markets on Tuesday, September 5. The rating was maintained by Jefferies on Tuesday, July 4 with “Hold”. Cowen & Co maintained it with “Hold” rating and $33.0 target in Thursday, January 11 report. Citigroup downgraded the shares of NOV in report on Monday, October 3 to “Sell” rating. The rating was maintained by Seaport Global on Monday, February 12 with “Sell”. The rating was maintained by Morgan Stanley on Tuesday, April 19 with “Underweight”.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Tuesday, July 18 by J.P. Morgan. The company was maintained on Monday, June 5 by Aegis Capital. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Thursday, November 9 by Canaccord Genuity. The firm has “Buy” rating by Roth Capital given on Monday, September 21. The firm has “Buy” rating by Roth Capital given on Monday, November 13. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, January 10. Roth Capital maintained the shares of NKTR in report on Tuesday, May 30 with “Buy” rating. As per Wednesday, August 16, the company rating was maintained by Jefferies. Jefferies maintained it with “Buy” rating and $23.0 target in Wednesday, October 18 report. TheStreet downgraded the stock to “Hold” rating in Wednesday, August 26 report.

Investors sentiment decreased to 1.4 in Q3 2017. Its down 0.49, from 1.89 in 2017Q2. It is negative, as 15 investors sold NKTR shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. Tocqueville Asset Management Limited Partnership has invested 0.07% in Nektar Therapeutics (NASDAQ:NKTR). Invesco Ltd owns 0.03% invested in Nektar Therapeutics (NASDAQ:NKTR) for 3.61M shares. Utd Services Automobile Association reported 194,880 shares. Fic Cap Inc accumulated 85,556 shares. Prudential Fincl owns 0.01% invested in Nektar Therapeutics (NASDAQ:NKTR) for 260,183 shares. Switzerland-based Swiss Fincl Bank has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). First Light Asset Mgmt Ltd Llc invested 3.82% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Voya Investment Mgmt Lc has invested 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Rothschild Ptnrs Limited Liability Corp reported 0.63% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Duquesne Family Office Limited Liability Corporation accumulated 1.17M shares. Alps Advsrs holds 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 153,958 shares. Stoneridge Invest Prtn Lc reported 0.04% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Highland Mngmt Lp reported 0.01% stake. Pinebridge Invs Limited Partnership holds 93,064 shares. Bnp Paribas Arbitrage Sa has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: